If we are going to defeat HIV, we cannot abandon our commitment to fully fund research, and we cannot walk away from our work ...

Gilead Sciences’ long-acting drug to block HIV could end the AIDS epidemic worldwide. But access and funding remain big questions. Bay Area Biotech Forum The Future of Bay Area Biotech ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are targeting the next goalpost: a cure.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales ...

A disruption in federal funds has jeopardized HIV testing and outreach in the U.S. South, and researchers warn of a ...

When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the ...

That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

Gilead Sciences Inc. has divulged bridged tricyclic carbamoylpyridone prodrugs acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infection.

The global HIV market is expected to reach $32.1 billion by 2033, driven by long-acting injectables and innovative therapies, ...